Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowNovo Nordisk A/S lost a bid in a US court to temporarily block Eli Lilly & Co. from using advertisements that claim its drugs are more powerful, a setback to Novo as it battles to regain a larger share of the obesity and diabetes drug markets.
U.S. District Judge Zahid Quraishi ruled Monday that Eli Lilly and Co. can continue to make the disputed claims in its ads while Novo proceeds with a lawsuit it filed in July in federal court in Trenton, New Jersey. The judge said that Novo’s case for a preliminary injunction was “less than persuasive” because it failed to show irreparable harm.
The dispute involves two sets of ads by Lilly. In one, the drugmaker claims its Zepbound obesity drug is superior to Novo’s Wegovy weight-loss medication. In the other, Lilly says its Mounjaro controls type 2 diabetes better than Novo’s Ozempic. The suit claims the comparisons amount to false advertising because Lilly relied on research that didn’t examine higher doses of Novo’s drugs that are more effective than its lower doses.
Both drugmakers seek to boost their share of a global market for obesity treatments that Bloomberg Intelligence estimates could reach $120 billion a year by 2030. Novo once dominated the market with Wegovy, but Lilly caught up with Zepbound and now has the lead in sales.
Lilly said in a statement that it was pleased with the ruling.
“Our focus has been and continues to be on the millions of people living with obesity, type 2 diabetes, and other chronic diseases,” the Indianapolis-based company said.
Novo didn’t immediately respond to a request for comment.
The judge said Novo offered only “speculative claims of harm” on its assertion that Lilly’s advertising is causing lasting damage to Novo’s clinical reputation.
“Novo baldly asserts, without citing or submitting any supporting evidence, that the challenged ads threaten future sales of Novo’s products and have harmed the goodwill Novo has cultivated over the years,” Quraishi wrote in his 25-page opinion. He separately ordered Lilly to respond to Novo’s lawsuit.
Novo chief executive Mike Doustdar’s strategy for clawing back market share includes litigation against competitors. In the July 21 lawsuit, Novo said Lilly’s ad campaigns for GLP-1 medicines were “maliciously and deliberately false.”
According to the Novo complaint, Lilly ads say people on Zepbound lost an average of 50 pounds, while Wegovy users lost an average of 33 pounds. Those ads relied on a study published in 2025 in which Zepbound beat Wegovy in a head-to-head trial. But Novo later got approval for a higher dose of its drug than that study used.
A better comparison, Novo argued, was either of two different studies. In one, Novo’s high-dose Wegovy showed average weight loss of 47 pounds. In another, Zepbound helped people lose an average of 48 pounds. The Food and Drug Administration approved the more intense Wegovy shot — which uses triple the previous highest dose — in March, and Novo started marketing it in April. Novo claims it’s too soon to share data on how many patients are taking the new triple dose.
In court filings and a two-day hearing in late August, Lilly’s lawyers urged Quraishi to reject Novo’s request for a preliminary injunction and its demand for corrective advertising.
“Lilly is beating Novo in the marketplace, and the reason is that Lilly’s medicines are more effective in treating diabetes and obesity,” company lawyers wrote in an Aug. 10 filing. “Lilly ran head-to-head clinical studies to show as much. Instead of advancing the science or running head-to-head studies of its own, Novo tries to compensate for its shortcomings with this lawsuit.”
A lawyer for Lilly, Gregg LoCascio, argued at an Aug. 28 hearing that the company’s ads were accurate and factual, and they don’t amount to false advertising. He argued that Novo had failed to show that it would succeed in the lawsuit or that the ads caused irreparable harm to the company.
“This case is clear,” LoCascio said. “Lilly’s science is unassailable. Lilly’s advertisements are truthful. Novo has not proven any entitlement, success on the merits, irreparable injury.”
Novo is seeking to recover the profits it lost through the advertising, as well as triple that amount under U.S. law. The lawsuit alleges Lilly violated U.S. and state false advertising and unfair competition laws, including the federal Lanham Act.
Please enable JavaScript to view this content.